Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer
Authors:
- 4 May 2024
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 206 (3) , 519-526
Abstract
Purpose Novel agents such as PI3K and mTOR inhibitors (PI3K/mTORi) have expanded treatment options in metastatic breast cancer (MBC). Nevertheless, mortality rates remain disproportionately high for Black patients and patients with lower socioeconomic status. Furthermore, clinical trials for these novel agents lacked diversity, so their toxicity profile in minority populations is uncertain. Methods We conducted a retrospective analysis of EHR-derived data from the Flatiron Health Database for patients with HR+, HER2− MBC. Multivariable logistic regression was used to evaluate factors associated with PI3K/mTORi use and toxicity outcomes. Results A total of 9169 patients with MBC were included in our analysis, of which 1780 (19.4%) received a PI3K/mTORi. We estimated the conditional total effect of insurance through Medicaid, and found lower odds of use of PI3K/mTORi among patients on Medicaid compared to those with commercial insurance (OR 0.73, 95% CI 0.54–0.99, p = 0.049). Odds of PI3K/mTORi use were higher for patients treated at an academic center (OR 1.28, CI 1.06–1.55, p = 0.01). Modeled as a controlled direct effect, Black/African American (Black/AA) race had no impact on odds of PI3K/mTOR use. Black/AA patients had twice the odds of developing hyperglycemia on PI3K/mTORi compared to White patients (OR 2.02, CI 1.24–3.39, p < 0.01). Conclusion This analysis of real-world data suggests that the use of PI3K/mTORi is influenced by socioeconomic factors. We also found racial disparities in toxicity outcomes, with Black/AA patients having twice the risk of hyperglycemia. Our findings call for greater efforts to ensure access to novel treatments and improve their tolerability in diverse populations.Keywords
Funding Information
- American Cancer Society
- Breast Cancer Research Foundation
This publication has 15 references indexed in Scilit:
- Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancerBreast Cancer Research and Treatment, 2022
- Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the USJAMA Network Open, 2022
- Racial Differences in Genomic Profiles of Breast CancerJAMA Network Open, 2022
- Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World DataBreast Cancer Research and Treatment, 2020
- Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2019
- Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centersCancer Medicine, 2018
- Association of Modifiable Risk Factors in Young Adulthood With Racial Disparity in Incident Type 2 Diabetes During Middle AdulthoodJAMA, 2017
- Socioeconomic status and breast cancer treatmentBreast Cancer Research and Treatment, 2017
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Socioeconomic, Rural-Urban, and Racial Inequalities in US Cancer Mortality: Part I—All Cancers and Lung Cancer and Part II—Colorectal, Prostate, Breast, and Cervical CancersJournal of Cancer Epidemiology, 2011